Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

News Room

News Room Search
News Room List
NO Title Date Viewers
35 Immunovant, HanAll’s partner, Announces Topline data from Phase 2 for IMVT-1401 in TED 2020-03-31 99
34 HanAll Biopharma Recorded Its Record-High Earnings Last Year 2020-02-27 101
33 HanAll Biopharma/Daewoong Announces Topline Results for HL036 Phase 3 (VELOS-2) Study at a Press Conference 2020-01-28 3416
32 HanAll Biopharma Begins Phase III Clinical Trial of HL036 in Patients with Dry Eye Disease 2019-03-12 3964
31 HanAll Biopharma Announces the Results of HL036’s Phase 2 Clinical Trial at the Ophthalmology Innovation Summit (OIS) in the U.S. 2018-10-29 3494
30 HanAll’s HL036 eye drops for dry eye syndrome treatment was approved of phase 2 clinical trial IND in China 2018-10-01 3652
29 HanAll Biopharma Announced 1H Results of Sales increased by 12.3% YoY · It Experienced the Turnaround with Operating Profit of KRW 1.9 billion 2018-08-14 3087
28 HanAll Biopharma’s New Antibody Drug, “HL161,” Accelerates its Global Development Through the Launch of Immunovant 2018-07-11 4423
27 HanAll Biopharma’s HL036 was Approved of its International Nonproprietary Name (INN) by the World Health Organization (WHO) 2018-06-25 3576
26 HanAll Biopharma and Daewoong Pharmaceutical Announced the Result of Phase 2 Clinical Trial of HL036 (a new drug for dry eye syndrome) in the U.S. 2018-05-29 3396
1 2 현재 페이지3 4 5 6